logo
After a stroke, more time in bed may affect memory, experts reveal

After a stroke, more time in bed may affect memory, experts reveal

Time of Indiaa day ago

Research indicates that increased time in bed after a mild stroke or TIA may negatively impact cognitive function. The study, involving brain scans and cognitive assessments, revealed a link between longer time spent in bed and poorer thinking and memory skills. These findings suggest disturbed sleep could signify adverse brain health in stroke survivors.
A good night's sleep is essential for health and emotional well-being. However, the same cannot be said for people who survived a stroke of transient ischemic attack (TIA). After a stroke or TIA, spending more time in bed, either sleeping or trying to sleep, may not be beneficial for cognitive function, reveals new research.
According to a new study published in
Neurology
, added sleep duration is associated with poorer thinking and memory skills. To understand the link between sleep and brain function in individuals who suffered a stroke, the researchers studied 422 adults with an average age of 66 from Edinburgh and Hong Kong who had recently experienced a mild stroke or TIA. One to three months following the event, all participants underwent brain scans, were asked to complete sleep questionnaires, and take cognitive assessments.
They found that spending more time in bed was linked to lower scores on tests of thinking and memory skills and changes in their brains that can lead to dementia or a second stroke.
What is a stroke
A
stroke
occurs when blood flow to part of the brain is interrupted or reduced, depriving brain tissue of oxygen and nutrients. A transient ischemic attack (TIA), often referred to as a 'mini stroke,' involves a brief blockage of blood flow.
While symptoms usually resolve within minutes or hours, a TIA can be an early warning sign of a more serious stroke.
Sleep after a stroke
The researchers observed that spending more time in bed does not equate to sleep. Difficulty falling asleep, fragmented sleep, poor quality sleep, or other problems are signs of a sleep disorder. The study found that both people with longer in-bed times and with longer sleep durations were more likely to have these brain changes.
The study, however, does not prove that these sleep issues cause these brain changes and thinking problems; it only shows an association.
What do experts think
Disturbed sleep is not great for health. 'These results show that disturbed sleep may be a marker of adverse brain health, even for people with mild strokes or TIAs. While many people know that a lack of sleep can lead to health issues, less is known about the effects of sleeping longer at night or spending a long time in bed trying to make up for having trouble sleeping—whether people are doing this consciously or not,' study author Joanna M.
Wardlaw, MD, of the University of Edinburgh in the United Kingdom said in a statement.
RFK Jr. Openly Tells World To Exit 'Bloated' WHO As Global Health Officials Watch Silently
In the study, the researchers found that people who spent a longer time in bed were more likely to have signs of damage to small blood vessels in the brain, including a greater volume of white matter hyperintensities, or areas in the white matter of the brain where brain tissue has been damaged. These participants were also more likely to have slightly lower scores on the test of thinking and memory skills.
People who had longer sleep duration were more likely to have small areas of microhemorrhages, or microbleeds, in the brain.
'More research is needed to confirm these findings and also to look at whether prolonged sleep has negative effects on people who have never had a stroke or TIA. Of course, research is also needed on whether improving people's sleep patterns after stroke could ward off some of these possible detrimental effects,' Wardlaw added.
One step to a healthier you—join Times Health+ Yoga and feel the change

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Anti Tobacco Forum opposes reported launch of nicotine-laced candies, toffees, and ice creams
Anti Tobacco Forum opposes reported launch of nicotine-laced candies, toffees, and ice creams

The Hindu

time36 minutes ago

  • The Hindu

Anti Tobacco Forum opposes reported launch of nicotine-laced candies, toffees, and ice creams

Anti Tobacco Forum (ATF), Mysuru, has opposed the reported launch of nicotine-laced candies, toffees, and ice creams by the tobacco industry in different parts of the world. In a statement issued on the eve of 'World No Tobacco Day 2025' on the theme 'Unmasking the appeal: Exposing industry tactics on tobacco and nicotine products', Vasanthkumar Mysoremath, convenor of ATF, Mysuru, said the nicotine-laced products launched by tobacco industry have emerged as the newest threat to public health from tobacco that is already claiming a large number of deaths worldwide. Designed to make the children and youth of today addicted to tobacco, these nicotine-laced products should be banned by the authorities like e-cigarettes, said Mr. Mysoremath. 'Tobacco industry is aiming at turning children into addicts to increase profits,' said Mr. Mysmoremath, while pointing out that WHO expects to create awareness in the minds of children/adults about the harmful effects of consuming tobacco products and wants countries to adopt stronger policies, including a ban on flavours that make tobacco and nicotine products more appealing for protecting public health. Pointing out tobacco kills 8 million people annually, he said tobacco consumption leads to various non-communicable diseases like cancer, blood pressure, lung infection, asthma, etc. Mr. Mysoremath regretted that many governments of signatory countries to the WHO-sponsored Framework Convention on Tobacco Control (FCTC) are found to be adopting dual standards in implementing the guidelines prescribed in FCTC. 'Some countries even subsidise tobacco cultivation by financing through supply of implements, concessions for fertilizers, easy loans through government banks, procuring excess grown tobacco by licensed and unlicensed growers, insurance money of policy holders invested in tobacco companies, elected political leaders assuring tobacco farmers to continue to grow quality tobacco and participating in events organised by tobacco farmers association and tobacco industry,' he said. 'Why is cultivation, production, and supply system of tobacco not being efficiently controlled is the big question?', he asked and wondered why the authorities, who had the discretion to either withdraw or cancel the permits and sanctions to grow tobacco and start tobacco products manufacturing facility,were not doing so. In order to help farmers give up tobacco farming and become debt-free, Mr. Mysoremath sought the creation of a corpus from the Budget or seek international funding and clear the outstanding loans of farmers as a one-time tobacco control measure and withdraw their licenses to cultivate tobacco with an affidavit that they will adopt alternate crops. 'This way, it is possible to effectively control the raw material supply to the tobacco industry,' he said.

New COVID variant NB.1.8.1 spreading fast in the U.S — is your vaccine effective? Will there be a summer surge?
New COVID variant NB.1.8.1 spreading fast in the U.S — is your vaccine effective? Will there be a summer surge?

Time of India

timean hour ago

  • Time of India

New COVID variant NB.1.8.1 spreading fast in the U.S — is your vaccine effective? Will there be a summer surge?

A new COVID variant, NB.1.8.1, is gaining traction in the United States just as summer approaches. Despite its rarity, it appears to be more transmissible than current strains. While not yet dominant, officials are closely monitoring its expansion and potential impact on public health. Although experts say it's too soon to predict whether the virus will lead to more COVID cases this summer, health officials are closely monitoring the variant as it spreads throughout the world. NB.1.8.1 is categorized by the World Health Organization (WHO) as a "variant under monitoring." A descendant of the Omicron JN.1 lineage, NB.1.8.1 was first identified in late January and has experienced a dramatic increase in cases worldwide in recent weeks, as per a report by Health. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Mountain Gear for Extreme Conditions Trek Kit India Learn More Undo How serious is NB.1.8.1 compared to other variants? The WHO's latest data shows that between April 21 and April 27, 10.7% of all sequenced COVID cases worldwide were caused by NB.1.8.1, up from 2.5% just one month earlier. According to Shira Doron, MD, chief infection control officer at Tufts Medicine, the variant is genetically distinct from LP.8.1, the dominant strain currently found in the United States. Live Events The variant may increase cases this summer because it seems more contagious than LP.8.1, the strain that is most prevalent globally. It appears to be no more effective than LP.8.1, though, at avoiding immunity from vaccinations or previous infections. The World Health Organization (WHO) has concluded that it does not present an additional health risk because it has not discovered any evidence that it causes more serious illness. What are the symptoms of NB.1.8.1? Experts concur that NB.1.8.1 symptoms resemble those of other COVID infections. The majority of NB.1.8.1 patients should anticipate the following symptoms: Chills or fever, coughing, congestion and sore throat, weariness, breathing difficulties and diarrhea. The good news is that NB.1.8.1 doesn't seem to make people sicker than earlier versions. Could there be a summer COVID surge? While now accounting for only a small portion of U.S. cases, specialists are closely monitoring NB.1.8.1. Six spike protein mutations are present in the variation, which may improve its ability to spread and elude antibodies. According to Amy Edwards, MD, an infectious disease specialist and assistant professor of pediatrics at the Case Western Reserve University School of Medicine, those mutations and early data point to NB.1.8.1 being marginally more transmissible, as per a report by NBC News. However, because of NB.1.8.1 or another variation, the number of COVID cases in the United States is probably going to increase this summer. Over the past few years, COVID has experienced two significant increases: one in the mid-to-late summer and another in the winter, Schaffner said, in contrast to influenza, which has one significant increase annually in the winter. Are NB.1.8.1 and current vaccines still effective? Experts say that current vaccines provide some protection, and the variant does not appear to be more severe. Some protection against NB.1.8.1 should come from preexisting immunity from vaccinations or previous infections. The Food and Drug Administration has asked drugmakers to update Covid vaccines to target the LP.8.1 variant this fall. Data from Pfizer and Moderna suggest the updated vaccines would offer protection against NB.1.8.1 as well. However, the FDA has said it will limit its approval of updated Covid shots to older adults and younger people with a medical condition that puts them at risk of severe illness. Doctors worry that pregnant people and children under 5 may be vulnerable to severe outcomes from Covid this winter. Even healthy adults who've been vaccinated before might not have optimal protection. According to Doron, new COVID booster shots from Pfizer, Moderna, and Novavax are also being developed and should be available in the early fall. Preliminary results indicate that they will be effective against NB.1.8.1 and other more prevalent strains in the United States. FAQs Does the new variant result in more severe illness? No, NB.1.8.1 does not appear to result in more severe symptoms than previous variants. Will current vaccines protect me from it? Yes, existing vaccines and boosters should provide some protection against NB.1.8.1.

WHO calls for maternal vaccine, monoclonal antibody to protect babies against RSV
WHO calls for maternal vaccine, monoclonal antibody to protect babies against RSV

Hans India

timean hour ago

  • Hans India

WHO calls for maternal vaccine, monoclonal antibody to protect babies against RSV

New Delhi: The World Health Organization (WHO) on Friday recommended all countries to use both maternal vaccine and a monoclonal antibody to protect babies against respiratory syncytial virus (RSV) -– the leading cause of acute lower respiratory infections in children globally. While the maternal vaccine -- RSVpreF -- can be given to pregnant women in their third trimester to protect their infant, the long-acting monoclonal antibody -- nirsevimab -- can be administered to infants from birth, just before or during the RSV season, stated the recommendations, published in the Weekly Epidemiological Record (WER). 'Every year, RSV causes about 100,000 deaths and over 3.6 million hospitalisations in children under the age of 5 years worldwide. About half of these deaths occur in infants younger than 6 months of age,' the WHO said. "The vast majority (97 per cent) of RSV deaths in infants occur in low- and middle-income countries where there is limited access to supportive medical care, such as oxygen or hydration," it added. Although RSV causes mild symptoms similar to the common cold, including runny nose, cough, and fever, it can lead to serious complications. This can include pneumonia and bronchiolitis -– in infants, young children, older adults, and those with compromised immune systems or underlying health conditions. Both RSVpreF and nirsevimab were recommended by the Strategic Advisory Group of Experts on Immunisation (SAGE) for global implementation in September 2024. In addition, the maternal vaccine received WHO prequalification in March 2025, allowing it to be purchased by UN agencies. While the vaccine can be given during routine antenatal care, nirsevimab is given as a single injection of monoclonal antibodies that starts protecting babies against RSV within a week of administration. It lasts for at least 5 months and can cover the entire RSV season in countries with RSV seasonality. The global health body recommends that infants receive a single dose of nirsevimab right after birth or before being discharged from a birthing facility. If not administered at birth, the monoclonal antibody can be given during the baby's first health visit. If a country decides to administer the product only during the RSV season rather than year-round, a single dose can also be given to older infants just before entering their first RSV season, the WHO said. The greatest impact on severe RSV disease will be achieved by administering the monoclonal antibody to infants under 6 months of age. However, there is still a potential benefit among infants up to 12 months of age, it added. 'RSV is an incredibly infectious virus that infects people of all ages, but is especially harmful to infants, particularly those born premature when they are most vulnerable to severe disease,' said Dr Kate O'Brien, Director of Immunisation, Vaccines, and Biologicals at WHO. 'The WHO-recommended RSV immunisation products can transform the fight against severe RSV disease, dramatically reduce hospitalisations, and deaths, ultimately saving many infants lives globally,' O'Brien added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store